Teva Of Israel Reports Progress In Trial Of Oral Version Of MS Drug
This article was originally published in PharmAsia News
Executive Summary
Israel's Teva Pharmaceutical Industries says a Phase III trial of its laquinimod, the oral version of its flagship product Copaxone (glatiramer) for treating multiple sclerosis, has been successful